香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） 年度業績公告 截至2025年12月31日止年度 本公司董事會欣然宣佈本集團截至2025年12月31日止年度的綜合年度業績，連同2024年 同期的比較數字如下。本集團根據國際財務報告會計準則編製的於報告期的綜合財務報 表已經審核委員會審閱。 於本公告內，「我們」指本公司，或如文義另有所指，指本集團。本公告所載若干金額及 百分比數字已約整，或已四捨五入至小數點後一位或兩位。任何表格、圖表或其他部分 所示總額與所列數額總和的任何差異乃因約整所致。 – 1 – 財務概要 | | 截至12月31日止年度 | | | --- | --- | --- | | | 2025年 | 2024年 | | | 人民幣千元 | 人民幣千元 | | 收入 | 1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 董事會會議日期 北京鷹瞳科技發展股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈， 董事會將於2026年3月31日（星期二）舉行董事會會議，藉以考慮及批准（其中包括） 本公司及其附屬公司截至2025年12月31日止年度之年度業績及其發佈，並考慮建議 派付末期股息（如有）。 承董事會命 北京鷹瞳科技發展股份有限公司 董事會主席 張大磊先生 香港，2026年3月19日 截至本公告日期，董事會包括執行董事張大磊先生、王林女士、秦勇先生及魏宇博 先生；及獨立非執行董事武陽豐博士、黃彥林博士及吳浩然先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） ...

公司名稱: 北京鷹瞳科技發展股份有限公司 (「本公司」) (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易 ...

Investment Rating - The report does not explicitly state an investment rating for the AI medical device industry Core Insights - The AI medical device industry is experiencing significant growth, with a market size increase from 125 million RMB in 2019 to 4.37 billion RMB in 2023, reflecting a compound annual growth rate (CAGR) of 143.33% [8] - The market is expected to continue expanding, projected to reach 52.49 billion RMB by 2028, with a CAGR of 68.58% [8] - The industry is characterized by a diverse range of applications and a growing number of approved products, indicating a broad market potential [5][9] Market Background - AI medical devices utilize artificial intelligence technology based on medical device data for medical purposes, with a wide range of applications and increasing regulatory support [5][6] - The industry has evolved through three major stages, from early expert systems to the current commercial application phase, marked by the approval of AI medical devices for clinical use [7] Market Status - The market size has shown substantial growth, with 81 AI medical devices approved by the end of 2023, up from 8 in 2020 [8] - The demand for AI medical devices is driven by the need to alleviate resource shortages in healthcare, with significant patient volumes and hospital bed utilization rates indicating ongoing challenges in the healthcare system [11][12] Market Competition - The competitive landscape features a tiered structure, with leading companies such as Shukun Technology and United Imaging in the first tier, followed by others like Pushang Medical and Aibot Medical [16] - Regulatory clarity has accelerated the approval process for AI medical devices, fostering a more competitive environment [16] Recommended Brands - Shukun Technology is recognized as a leader in AI and medical AI models, with a comprehensive product offering across the healthcare spectrum [19] - Deepwise Intelligent is noted for its strong R&D capabilities and a diverse AI product matrix [20] - Pushang Medical has innovated with AI surgical robots, enhancing precision in surgical procedures [21] - United Imaging is a major player in medical imaging equipment, with a robust AI product lineup [22] - Other notable companies include Bodo Medical, Neusoft Medical, and Eagle Eye Technology, each contributing unique innovations to the market [22][25][26] Development Trends - The industry is moving towards multi-modal technology integration and generative AI applications, enhancing diagnostic accuracy and clinical decision-making [30] - Regulatory frameworks are evolving to support product compliance and accelerate market entry for innovative solutions [32] - The market is expanding into grassroots healthcare and consumer-level applications, indicating new growth opportunities [33] - Collaboration between enterprises, academia, and research institutions is fostering innovation and international expansion in the AI medical device sector [34]

Group 1 - The robotics sector in the Hong Kong stock market has shown strong performance, with the robotics concept index rising by 1.76% as of the midday session on February 23 [1][2] - Notable stocks in the sector include ASMPT, which increased by 5.27%, and Huahong Semiconductor, which rose by 4.83% [1][2] - The previous trading day saw significant gains in robotics stocks, with Yujian closing up 21.4% and Sutech rising by 9.24% [3] Group 2 - The surge in the robotics sector is attributed to the prominent display of robots during the 2026 CCTV Spring Festival Gala, where several domestic robotics companies showcased their products [3][4] - The performances included advanced robotic capabilities, such as the first-ever robot Airflare and synchronized speech and facial movements [4] - The event has been interpreted as a significant step for the industry, moving from experimental phases to mainstream visibility, thus accelerating commercialization expectations [4] Group 3 - The Spring Festival Gala has led to a dramatic increase in robot product sales on e-commerce platforms, with Douyin reporting a 1680% year-on-year increase in GMV for robot products [5] - JD.com also experienced a surge in robot-related searches and orders, with a 300% increase in search volume and a 150% increase in order volume within two hours of the gala's broadcast [5] - The robotics industry is seeing positive developments, with companies like Sutech forecasting a net profit of at least 60 million RMB for Q4 2025, marking a new phase in their business development [5] Group 4 - Analysts from Guohai Securities highlight that the wave of electrification and intelligence in robotics is expected to open up broader market opportunities, suggesting a significant investment opportunity in the humanoid robotics sector [6] - Dongwu Securities notes that Tesla's Optimus is on track for mass production in 2026, indicating a narrowing supply chain focus on key components [6] - The report emphasizes the importance of technological iteration and cost reduction in the robotics sector, with specific attention to advancements in dexterous hands and lightweight materials [6]

Core Viewpoint - The stock price of Eagle Eye Technology-B has shown a significant increase of 5.22% over the past week, indicating positive market sentiment and potential growth in the AI healthcare sector [1][2]. Price Performance - The stock price fluctuated with a range of 12.75%, closing at 12.30 HKD on February 12, 2026. Technical indicators such as the MACD histogram turned positive, and the KDJ J-line rebounded from the oversold area to 71.296, suggesting improved short-term momentum [1]. Institutional Insights - Analysts have set a target average price of 13.29 HKD for Eagle Eye Technology-B, indicating potential upside from the current price level. There is a market focus on the alignment of its AI healthcare business with policy directions [2]. Recent Events - The AI healthcare industry has gained attention from policymakers, with a special study held by the State Council on February 11, 2026, emphasizing the deepening application of "Artificial Intelligence+" across various sectors. Additionally, OpenAI launched the ChatGPTHealth feature in January 2026, validating the commercialization path for AI in healthcare and enhancing industry optimism [3].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | 本月底法定/註冊股本總額： RMB 103,568,013 備註： 因本公司是於中華人民共和國註冊成立的公司，「法定股本」之概念不適用於本公司，上 ...

Core Viewpoint - Eagle Eye Technology-B (02251) has seen a decline of over 5%, currently trading at HKD 11.51, as the market shifts focus to the 2025 fiscal year performance [1] Financial Performance - For the first half of 2025, Eagle Eye Technology reported a revenue of RMB 83.713 million, representing a year-on-year decrease of 10.7% [1] - The company recorded a net profit of RMB 443,000 [1] - Since its listing, Eagle Eye Technology has consistently operated at a loss, with cumulative annual losses amounting to RMB 594 million from 2022 to 2024 [1]

Core Viewpoint - Eagle Vision Technology-B (02251) has seen a decline of over 5%, currently trading at HKD 11.51, as market attention shifts towards the company's performance for the fiscal year 2025 [1] Financial Performance - For the first half of 2025, Eagle Vision Technology reported a revenue of RMB 83.713 million, representing a year-on-year decrease of 10.7% [1] - The company recorded a net profit of RMB 443,000 for the same period [1] - Since its listing, Eagle Vision Technology has consistently operated at a loss, with cumulative annual losses amounting to RMB 594 million from 2022 to 2024 [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京鷹瞳科技發展股份有限公司 (「本公司」) (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103, ...